CRISPR Therapeutics AG (1CG.DU)
| Previous close | 39.20 |
| Open | 38.20 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 38.20 - 38.20 |
| 52-week range | 38.20 - 39.20 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 21 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireCRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing LNP mediated delivery to the liver for refractory hypertension targeting angiotensinogen (AGT) and acute hepatic porphyria (AHP) targeting 5’-aminolevulinate synthase 1 (ALAS1) - - CTX340™, targeting AGT in the liver, achieved durable editing of AGT and sust
GlobeNewswireCRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. The abstract describ
Fool.co.uk1 incredible growth stock I can’t find on the FTSE 100
The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional growth stocks. The post 1 incredible growth stock I can’t find on the FTSE 100 appeared first on The Motley Fool UK.
